Table 2.
Demographics, clinical characteristics, and prognostic biomarkers in patients with versus without BRAF, FBXW7, NRAS, and/or XPO1 mutations (n = 499a).
| Patient/disease characteristic | BRAF, FBXW7, NRAS, and/or XPO1 mutation | P | |
|---|---|---|---|
| Yes % (n = 73) | No % (n = 426) | ||
| Aged >70 years | 34 | 30 | 0.5 |
| Male | 78 | 71 | 0.2 |
| Binet stage Cb | 36 | 31 | 0.4 |
| Randomised arm chlorambucil | 52 | 47 | 0.5 |
| Non-response to treatment | 21 | 21 | 1.0 |
| ≥2 lines of treatment | 73 | 66 | 0.3 |
| Unmutated IGHV genes (>98% homology)a | 84 | 59 | 0.0002 |
| β2 microglobulin ≥4 mg/La | 55 | 47 | 0.3 |
| CD38 positive (cut-off 7%)a | 78 | 61 | 0.02 |
| Zap-70 positive (cut-off 10%)a | 65 | 47 | 0.02 |
| Trisomy 12a | 29 | 14 | 0.003 |
| 11q deletiona | 24 | 20 | 0.5 |
| Absence of 13q deletiona | 62 | 37 | 0.0001 |
| 17p deletiona | 8 | 5 | 0.5 |
| ATM mutation | 8 | 7 | 0.8 |
| BIRC3 mutation | 12 | 6 | 0.07 |
| EGR2 mutation | 1 | 3 | 0.5 |
| KRAS mutation | 15 | 4 | 0.0003 |
| NOTCH1 mutation | 21 | 11 | 0.02 |
| SF3B1 mutation | 15 | 26 | 0.05 |
| TP53 mutation | 15 | 9 | 0.09 |
aEight variables had missing data, with the no. of cases ranging from 356 to 464.
bBinet stage C disease was not significant because, while patients with these gene mutations were more likely than others to have anaemia (haemoglobin < 100 g/L; 33% versus 18%; P = 0.003), they were less likely to have thrombocytopenia (platelets < 100 × 109/L; 10% versus 21%; P = 0.02).